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Abstract
We have tested the susceptibility to neuraminidase inhibitors of 155 clade 2.1 H5N1 viruses from Indonesia, isolated
between 2006–2008 as well as 12 clade 1 isolates from Thailand and Cambodia from 2004–2007 using a fluorometric
MUNANA-based enzyme inhibition assay. The Thailand and Cambodian clade 1 isolates tested here were all susceptible to
oseltamivir and zanamivir, and sequence comparison indicated that reduced oseltamivir susceptibility we observed
previously with clade 1 Cambodian isolates correlated with an S246G neuraminidase mutation. Eight Indonesian viruses
(5%), all bearing I222 neuraminidase mutations, were identified as mild to extreme outliers for oseltamivir based on
statistical analysis by box plots. IC50s were from 50 to 500-fold higher than the reference clade 1 virus from Viet Nam,
ranging from 43–75 nM for I222T/V mutants and from 268–349 nM for I222M mutants. All eight viruses were from different
geographic locales; all I222M variants were from central Sumatra. None of the H5N1 isolates tested demonstrated reduced
susceptibility to zanamivir (IC50s all ,5 nM). All I222 mutants showed loss of slow binding specifically for oseltamivir in an
IC50 kinetics assay. We identified four other Indonesian isolates with higher IC50s which also demonstrated loss of slow
binding, including one virus with an I117V mutation. There was a minimal effect on the binding of zanamivir and peramivir
for all isolates tested. As H5N1 remains a potential pandemic threat, the incidence of mutations conferring reduced
oseltamivir susceptibility is concerning and emphasizes the need for greater surveillance of drug susceptibility.
Citation: McKimm-Breschkin JL, Barrett S, Pudjiatmoko, Azhar M, Wong FYK, et al. (2013) I222 Neuraminidase Mutations Further Reduce Oseltamivir Susceptibility
of Indonesian Clade 2.1 Highly Pathogenic Avian Influenza A(H5N1) Viruses. PLoS ONE 8(6): e66105. doi:10.1371/journal.pone.0066105
Editor: Todd Davis, Centers for Disease Control and Prevention, United States of America
Received January 13, 2013; Accepted May 1, 2013; Published June 11, 2013
Copyright:  2013 McKimm-Breschkin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Parts of this work were supported by the Australian Department of Agriculture, Forestry and Fisheries. No additional external funding was received for
this study. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.
Competing Interests: Zanamivir and peramivir were a gift from GlaxoSmithKline. JLM-B has received honoraria and/or travelassistance from GSK and Hoffman




Highly pathogenic avian influenza (HPAI) H5N1 remains
endemic in at least six countries including China, Egypt,
Indonesia, Viet Nam, Bangladesh and parts of India, and
continues to impact livelihoods and poultry farming in several
other countries in South East Asia [1]. While not yet capable of
human to human transmission, concerns regarding potential
emergence of a pandemic virus remain as millions of poultry are
infected annually. Sporadic transmission from poultry to humans
continues; as of February 2013, the largest numbers of human
cases reported to WHO were from Indonesia, Egypt, and Viet
Nam (n= 192, 169, and 123 respectively) [2]. The case fatality
rates vary significantly across these three countries, ranging from
36% (60/169) in Egypt to 83% (160/192) in Indonesia. This
variation may reflect delays in initiating treatment including
antiviral therapy, but may also represent some inherent variability
in the drug susceptibility of different isolates.
Two drugs are licensed globally for the treatment and
prevention of influenza, zanamivir (Relenza) administered by oral
inhalation, delivering high doses to the upper respiratory tract, and
oseltamivir (Tamiflu) which is taken orally and disseminates
systemically. A third drug, peramivir, is licensed in Japan and
South Korea for intravenous administration, but it is still
undergoing clinical trials elsewhere. These drugs target the
neuraminidase (NA) enzyme, a surface glycoprotein of the
influenza virus, and are effective against all strains of influenza
due to the high degree of conservation at the NA active site.
Oseltamivir is the drug of choice for treatment of H5N1 infected
patients due to concerns regarding potential systemic infection.
Oseltamivir is also the primary drug stockpiled globally for
potential pandemics. All these drugs, classed as neuraminidase
inhibitors (NAIs), are designed based on 2,3-dehydro-2-deoxy-N-
acetylneuraminic acid (DANA) a transition state analogue of the
sialic acid substrate. Zanamivir has a single modification of a C4-
guanidinium group compared to DANA [3], while oseltamivir has
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both a C4-amino group, and a pentyl ether group replaces the
glycerol side chain in DANA [4]. Peramivir has features of both
inhibitors, with a C4-guanidinium group and a pentyl side chain
[5]. Both oseltamivir and peramivir require structural rearrange-
ments in the active site for high affinity binding. Residue E276
rotates to form a salt link to R224, creating the pocket which
accommodates their hydrophobic side chains. Because of the
structural changes required to accommodate the binding of these
inhibitors, we had predicted resistance was more likely to arise
against oseltamivir than zanamivir [6]. Widespread resistance to
oseltamivir was demonstrated by the global spread of the
oseltamivir resistant seasonal H1N1 influenza strain during
2007–9 [7–10].
Despite the millions of poultry infected with HPAI, routine
surveillance for drug susceptibility has not been conducted on
avian isolates with information primarily from small studies [11–
15]. Analysis of NA gene sequences in public data bases has
identified known NAI resistance mutations in HPAI H5N1 avian
virus isolates. Sequence analysis revealed mixed populations of
oseltamivir sensitive wild type viruses and some with the H274Y
mutation conferring oseltamivir resistance from chickens, ducks
and geese [16]. Virus with a N294S mutation was detected in
ducks [17]. However, while sequencing approaches can detect
mixtures of wild type and mutant populations, only known
mutations can be detected [18]. In contrast, screening using the
NA enzyme inhibition assay will detect phenotypic differences
caused by any mutation, but the resistant population generally
needs to be in excess over the wild type population to detect a shift
in susceptibility [19]. The technique also requires level 3
biocontainment facilities for virus culture to produce sufficient
material to be analyzed in the assay, which can be a barrier to
large scale surveillance of drug susceptibility.
We previously evaluated a panel of clade 1 HPAI H5N1 viruses
from Viet Nam and Cambodia and clade 2.1 viruses from
Indonesia using a fluorometric 4-Methylumbelliferyl N-acetyl-a-
D-neuraminic acid (MUNANA) based enzyme assay. We showed
that the clade 2.1 viruses circulating in Indonesia had a lower
susceptibility to oseltamivir with a mean IC50 of 11.5 nM
(IC50 = concentration of drug to inhibit enzyme activity by 50%)
compared to the clade 1 isolates with a mean IC50 of 0.5 nM [13].
We suggested that an H252Y difference in the NA between clade
1.1 and clade 2.1 respectively was the most likely cause of the
lower oseltamivir susceptibility. This was subsequently confirmed
by others using mutagenesis [20,21]. The Y252 impairs the
rotation of E276 in the NA active site, which is necessary to form
the hydrophobic pocket to accommodate the pentyl ether side
chain of oseltamivir. Susceptibility to zanamivir is not affected.
The reduced susceptibility to oseltamivir in vitro also corresponds
to reduced susceptibility in animal models [20,22].
We also reported that some HPAI H5N1 viruses isolated from
the Kandal province in Cambodia in 2005 had approximately 6–
7-fold reductions in susceptibility to oseltamivir compared to the
isolates from 2004, but there was no difference in zanamivir
susceptibility. We did not know whether this was a regional cluster
or whether this was more widespread [13]. Based on observations
of Rameix-Welti et al. [15] we suggested that a S246G mutation
may be associated with this reduced susceptibility, but sequence
data was not available at that time. The availability of further
isolates from Cambodia has now enabled us to test this hypothesis
further.
We aimed to extend the scope of our previous study by
evaluating the drug susceptibility of a large panel of HPAI H5N1
virus isolates from Indonesia from 2006–2008 as well as avian
isolates from Cambodia and Thailand from 2004–2007. Samples
were screened against oseltamivir and zanamivir using the
fluorometric MUNANA-based enzyme assay. Based on box plot
statistical analysis, those identified as outliers were also screened
against peramivir. Overall, higher IC50s were confirmed for
oseltamivir in clade 2.1 HPAI H5N1 viruses circulating in
Indonesia compared to clade 1viruses. But more disturbingly,
eight Indonesian viruses (5%), all bearing I222 mutations were
identified statistically as mild to extreme outliers for oseltamivir.
None of the H5N1 isolates tested demonstrated reduced suscep-
tibility to zanamivir (IC50s all ,5 nM).
Results
We used samples selected from our previous work as control
reference strains [13] for the enzyme inhibition assays. These
included a clade 1.1 virus from Viet Nam (A/chicken/Vietnam/
08/2004) which was sensitive to both zanamivir and oseltamivir, a
clade 1 virus from Cambodia (A/goose/Kandal/2005) which had
demonstrated a 6 to 7-fold reduction in oseltamivir susceptibility,
and an Indonesian clade 2.1 virus A/chicken/Wates/126/2005,
which had previously displayed around a 15-fold reduction in
oseltamivir susceptibility compared to the clade 1.1 Viet Nam
viruses we had tested [13].
Susceptibility of H5N1 Viruses from Cambodia to NA
Inhibitors
All Cambodian viruses isolated from 2005–2007 displayed high
susceptibilities to oseltamivir, with similar low IC50s as seen for the
clade 1.1 reference virus from Viet Nam (Table 1) and previous
2004 Cambodian isolates. Sequencing of the NAs of Cambodian
isolates tested here and previously [13] revealed that all of the
Kandal 2005 isolates previously identified with higher IC50s for
oseltamivir had a S246G mutation. (Note due to differences in the
length of the NA genes between avian and human N1 NAs N2
sequence numbering is used throughout the manuscript). This
finding is in agreement with Rameix-Welti et al. [15] who
demonstrated that an H5N1 NA with an S246G mutation had
an eight-fold higher IC50 for oseltamivir. They proposed that the
interaction of S246 with the pentyl ether side chain contributed to
the affinity of the NA for oseltamivir. Three changes in the stalk
common to these isolates, A45T, T51A, S61A (numbering based
on the HPAI H5N1 stalk, due to difficulty in aligning H5N1 and
N2 stalk amino acids because of insertions/deletions between
them), and D402E in the NA head were unlikely to have affected
the NA sensitivity of the 2005 Kandal viruses.
Susceptibility of H5N1 Viruses from Thailand to NA
inhibitors
The NAI susceptibilities were determined for five avian clade
1.1 H5N1 viruses isolated from Thailand during 2004–2006
(Table 2). Surprisingly only one isolate, A/chicken/Suphanburi/
2509/2004, had comparable susceptibility to the clade 1.1 Viet
Nam reference virus (Table 2). The other four viruses from 2005–6
had approximately two-fold higher IC50s for zanamivir than
observed with the Viet Nam reference virus or the sensitive
Cambodian clade 1.1 isolates tested here (Table 1). Although
several amino acid differences were detected between the NA
sequences of the Cambodian and Thailand viruses, there was no
consistent difference identified that could account for the slightly
altered susceptibility. The A/chicken/Ayudhya/2057/2004 iso-
late which had the highest IC50 for both zanamivir and oseltamivir
had two unique changes (P154S and I314L, N2 numbering) as
compared to other clade 1.1 and clade 2.1 strains investigated here
(except for A/chicken/West Java/Tja-31/2008 a clade 2.1 virus
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from Indonesia which also had P154S). In the region of P154 other
amino acids including D151, R152 and R156 are known to be
involved in substrate or inhibitor binding [23,24] and mutations at
these sites can reduce NAI susceptibility [25]. Hence a mutation at
position 154 could impact on inhibitor binding. The IC50s for A/
chicken/West Java/Tja-31/2008 for both inhibitors were still
below 5 nM, suggesting that these mutations would be unlikely to
have any clinical significance.
Susceptibility of H5N1 Viruses from Indonesia to NA
Inhibitors
The virus samples from Indonesia were obtained in two batches
over a year apart. The first contained 92 viruses primarily
collected in 2007, and the second batch contained 63 viruses
collected from 2006–2008. Due to the timing and large numbers
of viruses, testing for each batch was carried out in multiple assays
against both zanamivir and oseltamivir, but we used the same
control reference viruses to enable comparison. For such large
numbers of isolates, resistant viruses with elevated IC50s can distort
the mean, hence box and whisker plots are used to demonstrate
the median and the spread of IC50s, as well as to identify statistical
outliers [26,27] (Fig. 1). The summary of the statistical analysis is
presented in Table 3.
All of the Indonesian clade 2.1 viruses displayed elevated IC50s
to oseltamivir as compared to the clade 1.1 reference virus from
Viet Nam and the other clade 1.1 viruses tested here from
Cambodia and Thailand (Tables 1 and 2). The median IC50 was
25 nM with 65% (100/155) with IC50s between 20 and 30 nM,
and 15% (24/155) had values over 30 nM (Fig. 1). Based on the
statistical definition of mild and extreme outliers as discussed in the
Materials and Methods we identified two mild outliers for
oseltamivir with IC50s between 42 and 63 nM and five extreme
outliers with IC50s between 63–350 nM (Table 4) in the first batch
and one extreme outlier in the second batch with an IC50 of
62.4 nM. The IC50s of even the mild outliers to oseltamivir were
more than 50-fold higher than the reference Viet Nam clade 1.1
IC50 with the most extreme outlier being up to 500-fold higher.












A/chicken/Cambodia/CMB07.71LC3/2007 1.30 0.7 0.51 0.7
A/duck/Cambodia/CMB07.72/2007 1.28 0.7 0.65 0.9
A/chicken/Cambodia/CMB07.71LC4/2007 0.83 0.5 0.75 1.1
A/chicken/Cambodia/CMB07.71LC1/2007 0.99 0.6 0.77 1.1
A/chicken/Cambodia/CMB07.71LC2/2007 1.07 0.6 0.78 1.1
A/duck/Cambodia/CMB06.58/2006 1.43 0.8 0.81 1.1
A/chicken/Cambodia/CMB05.142/2005 1.53 0.8 1.35 1.9
Mean (SD) 1.20 (0.25)a 0.80 (0.26)a
Reference Clade 1.1 Strains Mean (SD) Mean (SD)
A/chicken/Vietnam/08/2004b 1.80 (0.73)b 0.71 (0.26)
A/goose/Kandal/2005c 1.68 (0.8) 7.07 (1.33)
aSamples were all assayed with a 30 min preincubation with inhibitor, and then MUNANA was added and reactions were stopped after 60 min and read. Samples were
tested in duplicate and means were calculated from the log10 transformed values, then back transformed.
bA/chicken/Vietnam/08/2004 was used as the zanamivir and oseltamivir sensitive reference. Mean and standard deviation of six H5N1 assays carried out during the
same period.
cVirus used as an elevated oseltamivir IC50 reference from previous testing. Mean and standard deviation of six H5N1 assays carried out during the same period.
doi:10.1371/journal.pone.0066105.t001
Table 2. Susceptibility of clade 1.1 HPAI H5N1 isolates from Thailand to zanamivir and oseltamivir in the enzyme inhibition assay.









A/chicken/Suphanburi/2509/2004 1.9 1.1 0.61 0.9
A/chicken/Saraburi/10713/2005 3.5 1.9 0.68 1.0
A/chicken/Pichit/606988/2006 3.5 1.9 0.69 1.0
A/duck/Suphanburi/14376/2005 3.6 1.9 1.1 1.5
A/chicken/Ayudhya/2057/2004 4.7 2.6 1.8 2.5
Mean (SD) 3.43 (1.0)a 0.97 (0.5)a
Reference clade 1.1 strain Mean (SD) Mean (SD)
A/chicken/Vietnam/08/2004b 1.80 (0.73)b 0.71 (0.26)
aSamples were all assayed with a 30 min preincubation with inhibitor, and then MUNANA was added and reactions were stopped after 60 min and read. Samples were
tested in duplicate and means were calculated from the log10 transformed values, then back transformed.
bVirus used as zanamivir and oseltamivir sensitive reference. Mean and standard deviation of six H5N1 assays carried out during the same period.
doi:10.1371/journal.pone.0066105.t002
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While there was one outlier to zanamivir in batch one with an
IC50 of 4.7 nM, this is less than three-fold higher than the
reference Viet Nam virus, and is considered within the normal
susceptible range for human isolates [26]. This isolate displayed no
reduced susceptibility to oseltamivir.
The NA sequences of all 155 clade 2.1 viruses (batches 1 and 2)
were aligned to determine whether those isolates identified as mild
or extreme outliers for either drug had any known mutations
(Table 4). The mild outlier to zanamivir A/chicken/Tabanan/
BBVD-307/2007 had a unique V263I change compared to other
clade 2.1 isolates tested here. The I263 is also present in most of
the clade 1.1 Cambodian strains tested here, but their IC50 values
were 1.5 nM or less for zanamivir. However, as multiple
differences exist between the clade 1 and clade 2.1 NA sequences,
it is possible that a given mutation could have an impact on one
clade but not the other.
Overall for oseltamivir, there were four mild or extreme outliers
with I222T NA mutations, one extreme outlier with an I222V
mutation and three extreme outliers which had I222M NA
mutations (Table 4). One virus with the I222M mutation (A/
Figure 1. Box plots of means of IC50s for zanamivir and oseltamivir for Indonesian HPAI H5N1 isolates. Means were calculated from the
log10 transformed duplicate values, then back transformed. Boxes represent the 25th to 75th percentiles, and horizontal lines within the boxes
represent the median values. The difference between the 25th–75th percentiles is defined as the interquartile range (IQR). The ends of the solid lines
extending either side of the boxes represent the approximate 95% confidence limits. Mild and extreme outliers lie outside these 95% confidence
limits at 1.5x or 3x the IQR respectively from the 75th percentile. Viet clade 1 is the pooled results of all the assays using the reference clade 1.1 A/
chicken/Vietnam/08/2004, Indon#1 = clade 2.1 Indonesian samples from batch 1, and Indon #2 = samples from batch 2. (A) Only one outlier was
identified for zanamivir whereas there were 8 mild or extreme outliers for oseltamivir (B).
doi:10.1371/journal.pone.0066105.g001














Number of viruses tested 91 92 63 63
Meanb (range) 1.15 (0.28–4.67) 25.1c(10.6–349) 1.55 (0.75–2.62) 23.3(12.6–62.4)
Median 1.12 24.9 1.6 24.4
IQRd 0.89–1.51 21.2–28.2 1.3–1.9 20.4–26.4
Mild High Outlierse 1 (.3.3) 2 (.42.4) 0 (.3.2) 0 (.40.0)
Extreme High Outliersf 0 (.7.2) 5 (.63.7) 0 (.5.6) 1 (.60.5)
Reference Controls [13] Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Cl 1.1 A/chicken/Vietnam/08/2004g 1.80 (0.73) 0.71 (0.26) 2.80 (0.89) 0.84 (0.21)
Cl 1.1 A/goose/Kandal/2005h 1.68 (0.8) 7.07 (1.33) 2.94 (0.73) 6.55 (1.10)
Cl 2.1 A/chicken/Wates/126/2005i 0.92 (0.35) 15.9 (4.03) 1.61 (0.37) 19.80 (4.73)
aSamples were all assayed with a 30 min preincubation with inhibitor, and then MUNANA was added and reactions were stopped after 60 min and read. Samples were
tested in duplicate and means and SDs for reference controls are from all assays in each batch, with six assays in the first batch and five in the second.
bMeans for each batch were calculated on log10 transformed data, and then back transformed.
cExcluding 2 most extreme outliers with IC50s .260 nM.
dIQR Interquartile range representing the range in which 50% of values fall (25th-75th percentile).
eMild outliers defined as 1.5xIQR from the 75th percentile.
fExtreme outliers defined as 3xIQR from the 75th percentile.
gClade 1 strain sensitive to both zanamivir and oseltamivir.
hClade 1 Cambodian strain with small reduction in oseltamivir sensitivity.
iClade 2 Indonesian strain with higher reduction in oseltamivir sensitivity.
doi:10.1371/journal.pone.0066105.t003
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chicken/Siak/BPPVRII-635/2007) was not inhibited by either
drug, which is especially unusual for zanamivir. Based on previous
experience this suggested the isolate was a co-infection of H5N1
with Newcastle disease virus (NDV), which also has NA enzyme
activity. NDV was subsequently also identified in this sample. This
should be noted as a warning to those carrying out NAI
susceptibility testing on avian isolates that NDV can lead to
incorrect interpretations of the presence of highly resistant
influenza viruses. In this case there was coincidentally a virus
with an I222M mutation which does cause high level oseltamivir
resistance. All I222M variants were from central-Sumatra and two
had identical hemagglutinin (HA) and NA sequences. The NAs of
the three viruses with I222T mutations from Denpasar and
Tabanan, Bali all had identical amino acid sequences including a
V321I not seen in any of the other isolates here, as well as an I8M
(H5N1 stalk numbering) and S48L (H5N1 stalk numbering) in the
stalk region. There were however several nucleotide differences.
The fourth I222T virus was isolated from Pidie, which is
geographically distant (north end of Sumatra) from where the
other I222T mutant viruses were isolated, and bore two additional
amino acid changes. The A/Muscovy duck/Magelang/BBVW-
415/2007 virus which was an extreme outlier to oseltamivir with
an IC50 of 62.4 nM (Table 4), originated from Java. Sequence
analysis revealed its NA had several variations in the stalk region
compared to all other isolates, and it had a unique mutation of
I222V.
Mutations leading to resistance to the NAIs often lead to a loss
of fitness of the mutant virus, which may be outgrown by a wild
type virus upon culturing. Close inspection of the sequencing
chromatographs of all the I222 mutants showed no evidence of
mixed sequences of wild type and mutant at position 222 in any of
the isolates. This indicated that these mutant viruses were
sufficiently fit to compete with the wild type virus in the birds
and/or after egg culture to become the dominant species in our
samples.
We then analyzed sequences for unique variations which had
previously been associated with altered NAI susceptibility and then
cross-checked their IC50s. Sequence analysis of the NA of A/
chicken/Bangli/BBVD-562/2007 revealed an I117V mutation
(Table 4). There have been reports of I117V conferring reduced
susceptibility to oseltamivir during surveillance of other H5N1
viruses [11,12,28,29]. This virus had an IC50 in the higher range
for each drug (zanamivir 2.9 nM, oseltamivir 36 nM). While not a
mild outlier statistically, these values were well above the median
for oseltamivir (25 nM).
Analysis of NA Inhibitor Binding by IC50 Kinetics
The NAIs are described as slow binding inhibitors, and loss of
slow binding is seen with many resistant viruses [30]. While
laboratories routinely use a single time point for measuring the
IC50, we have developed real time IC50 kinetics assays which
additionally demonstrate whether an inhibitor is fast or slow
binding by comparing the IC50s over 60 min with and without
preincubation of NAI and virus [30]. If the NAI is slow binding,
preincubation with virus is needed for maximum binding. Hence
the final IC50 without preincubation is higher than the initial IC50
with preincubation. If the final IC50s for both sets of reactions are
similar (ratio of ,1) this indicates changed kinetics due to fast
binding and dissociation or a partial loss of slow binding and faster
dissociation of the NAI.
IC50 kinetics for the mutant viruses were compared to clade 1.1
and clade 2.1 reference controls, A/chicken/Vietnam/08/2004
and A/chicken/Bangli/BBVD-563/2007 respectively. This latter
strain was used as the reference due to depletion of the A/
chicken/Wates/126/2005 virus by the time these assays were
carried out. It was considered a representative virus of the batch
with an IC50 around the median.
For all wild type and mutant viruses for zanamivir and
peramivir the final IC50s without preincubation were all higher
than the initial IC50s with preincubation, indicating slow binding
(Fig. 2). Ratios of the final IC50s were also all .2.0 (Table 5),
except for the A/chicken/Ayudhya/2057/2004 clade 1 isolate
with the P154S and I314L mutation with zanamivir and also with
oseltamivir (ratio ,1). Inspection of the graphs (Fig. 2) shows that








A/chicken/Tabanan/BBVD-307/2007 4.7 2.6 11.8 16.6 V263I
A/chicken/Bangli/BBVD-562/2007 2.9 1.6 36.0 50.7 I117V
A/chicken/Pidie/BPPVRI-15/2007 2.8 1.6 42.5 59.9 I222T
A/chicken/Tabanan/BBVD-142/2007 1.7 0.9 63.2 89.0 I222T
A/chicken/Denpasar/BBVD-456/2007 2.2 1.2 68.9 97.0 I222T
A/chicken/Tabanan/BBVD-107/2007 1.7 0.9 75.1 105.8 I222T
A/chicken/Kuantan Singingi/BPPVRII-620/2007 0.7 0.4 268 377.5 I222M
A/chicken/Padang Panjang/BPPVRII-272/2007 1.9 1.1 349 491.5 I222M
A/chicken/Siak/BPPVRII-635/2007c ND – ND – I222M
A/Muscovy duck/Magelang/BBVW-415/2007 2.6 1.4 62.4 87.9 I222V
Reference strain Mean (SD) Mean (SD)
A/chicken/Vietnam/08/2004b 1.8 (60.73) 0.71 (60.26)
aSamples were all assayed with a 30 min preincubation with inhibitor, and then MUNANA was added and reactions were stopped after 60 min and read. Values are the
mean of duplicate reactions.
bFold difference was compared to the means of the six batch 1 assays for the sensitive reference clade 1.1 A/chicken/Vietnam/08/2004.
cSample not inhibited by either drug; co-infected with Newcastle disease virus.
doi:10.1371/journal.pone.0066105.t004
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Figure 2. IC50 kinetics for wild type and mutant H5N1 isolates for zanamivir, oseltamivir and peramivir. Comparison of IC50s after each
10 min without preincubation of virus with inhibitor (2) and with a 30 min preincubation (+) of virus with inhibitor. After addition of MUNANA
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the increased IC50s for this virus correlated with a more rapid
dissociation of these two NAIs. A small increase in dissociation
rates for zanamivir and peramivir was also observed for the I222
mutants.
For oseltamivir binding to the Indonesian reference virus, the
final IC50 without preincubation was higher than the initial IC50
with preincubation, but the final ratio of the two reactions was ,1
(Table 5). This confirmed our previous observation of partial loss
of slow binding, and faster dissociation compared to the clade 1.1
virus, which had a 7-fold higher IC50 without preincubation [13].
The I222/M/V/T mutations all led to complete loss of slow
binding of oseltamivir. Similar high IC50s were seen with or
without preincubation with oseltamivir (ratio ,1 Table 5).
While the box plots identified Indonesian outliers with I222
mutations, because the median IC50 is already almost 30-fold
higher than the sensitive clade 1.1 mean IC50s this approach does
not identify all viruses which could be more resistant compared to
sensitive clade 1.1 viruses. We therefore analyzed the kinetics of
binding of the inhibitors for those viruses with IC50s around
30 nM to see if we could identify additional viruses with altered
kinetics of NAI binding [30–32]. We identified four additional
isolates which were no longer slow binding (Fig. 3). The first of
these was A/chicken/Bangli/BBVD-562/2007, which correlated
with the I117V mutation. The second isolate, A/chicken/West
Java Tangerang/PTB6/2008 had unique S189G, E258K and
G385E mutations. None of these are highly conserved structural
or functional residues however, there was clearly an impact on the
kinetics of oseltamivir binding. The third isolate A/chicken/West
Java/Tja-31/2008 had three unique mutations compared to other
clade 2.1 isolates tested, P154S, M257I, M306I. Interestingly we
had observed a P154S in one clade 1.1 Thailand isolate which had
a small impact on drug binding, so this may be the contributing
mutation here, which in addition to the H252Y leads to complete
loss of slow binding. The fourth isolate A/chicken/Payakumbuh/
BPPVRII-307/2007 had no unique variation, hence there must be
a combination of amino acids altering its kinetics of drug binding.
Thus it appears that a number of variations can lead to loss of slow
binding, other than those in known sites. None of these viruses
demonstrated loss of slow binding to zanamivir or peramivir.
Discussion
The importance of surveillance of the drug susceptibilities of
human influenza isolates has led to widespread testing of NAI
susceptibility of circulating human influenza strains in recent
years, especially since the emergence of the oseltamivir resistant
H1N1 seasonal strain in 2008 [7–10]. There are still concerns that
a variant HPAI H5N1 strain may yet cause a pandemic, hence
knowledge of the spectrum of drug susceptibility of H5N1 viruses
is also critical for the management of patients infected with H5N1,
as well as for stockpiling strategies for a potential pandemic arising
from an H5N1 variant. There has been limited availability of
avian influenza isolates for testing of drug susceptibilities, although
even in those few tested there have been reports of decreased
susceptibility of clade 2 isolates compared to clade 1 isolates [13],
and additional mutations which have affected susceptibility
including I117V, V116A, S246N, S246G and I222L [11,12,15].
In collaboration with the Indonesian Ministry of Agriculture,
CSIRO AAHL has been involved with an FAO-implemented
OFFLU technical project monitoring HA genetic and antigenic
changes in Indonesian clade 2.1 HPAI H5N1 isolates. In addition
to the information on the effects of HA drift mutations on
substrate both assays were incubated for 60 min. Results for each 10 min interval are the means of duplicate assays. A lower initial 10 min IC50 in the
(+) reaction compared to the final 60 min IC50 in the (2) reaction indicates slow binding, e.g. all NAIs with the clade 1 wild type, (A) zanamivir, (B)
oseltamivir and (C) peramivir. Similar IC50s in both assays demonstrate a loss of slow binding, e.g. all the I222 mutants with oseltamivir (B). A greater
increase in IC50 from 10–60 min in the (+) reaction relative to the control virus indicates faster dissociation of the inhibitor compared to the wild type,
e.g. clade 2.1 wild type with oseltamivir (B). Cl 1 wt=Clade 1 wild type A/chicken/Vietnam/08/2004, Cl 1 P154S= clade 1.1 A/chicken/Ayudhya/
2057/2004, Cl 2 wt=Clade 2.1 wild type A/chicken/Bangli/BBVD-563/2007, Cl 2 I222T= clade 2.1 A/chicken/Denpasar/BBVD-456/2007, Cl 2
I222M= clade 2.1 A/chicken/Padang Panjang/BPPVRII-272/2007, Cl 2 I222V= clade 2.1 A/Muscovy duck/Magelang/BBVW-415/2007.
doi:10.1371/journal.pone.0066105.g002
Table 5. Comparison of 60 min IC50 values for enzyme inhibition assays with and without preincubation with inhibitor for wild
type and mutant viruses.
Zanamivir IC50 nM Oseltamivir IC50 nM Peramivir IC50 nM
Preincubation stepa
H5N1 virusa NA Mutation (2) (+) Ratio (2)/(+) (2) (+) Ratio (2)/(+) (2) (+) Ratio (2)/(+)
Clade 1.1
A/chicken/Vietnam/08/2004 Wild type 13.2 2.1 6.3b 4.3 0.6 7.2b 6.2 0.7 8.9
A/chicken/Ayudhya/2057/2004 P154S 4.2 4.7 0.9c 2.1 1.8 1.2c 2.8 0.4 7
Clade 2.1
A/chicken/Bangli/BBVD-563/2007 Wild type 11.2 1.3 8.6 21.4 19.6 1.1 5.4 0.6 9
A/chicken/Denpasar/BBVD-456/2007 I222T 13.3 2.2 6.0 78.2 86.1 0.9 12.4 1.3 9.5
A/chicken/Padang Panjang/BPPVRII-272/2007 I222M 5.9 2.6 2.3 254.0 310.3 0.8 5.3 2.0 2.7
A/Muscovy duck/Magelang/BBVW-415/2007 I222V 15.1 3.1 4.9 63.7 70.1 0.9 9.4 1.9 4.9
a(2)Virus, inhibitor and MUNANA substrate were added simultaneously with no preincubation. (+) virus and inhibitor were preincubated for 30 min, then MUNANA was
added. Both reactions were followed for 60 min. Values are the means of duplicate reactions.
bSlow binding is demonstrated by a higher IC50 without preincubation compared to with preincubation; ratio of (2)/(+) .2.0.
c(2)/(+) ratio ,1 shows changed kinetics, which can be due to fast binding and fast dissociation, as seen for all the I222 mutants with oseltamivir, or slow binding, but
fast dissociation as seen for the P154S mutant with zanamivir and oseltamivir, as shown in Fig. 2.
doi:10.1371/journal.pone.0066105.t005
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antigenicity, these viruses provided a valuable opportunity for
screening for susceptibility to the NAIs. The HPAI H5N1 viruses
were from both commercial and backyard poultry, and covered
different geographic areas of Indonesia. We also performed assays
on a few virus samples from Cambodia and Thailand. Testing 166
HPAI H5N1 isolates in the MUNANA based enzyme inhibition
assay detected no virus with an IC50.5 nM for zanamivir. In
contrast we saw a higher mean and median IC50 for oseltamivir
for the Indonesian isolates (,25 nM) than in our previous report
(11 nM). Of more concern is that we identified a number of clade
2.1 isolates from Indonesia which were phenotypically and
genotypically resistant to oseltamivir. These mutations also
resulted in different binding properties in our IC50 kinetics assays,
with loss of slow binding to oseltamivir, a feature seen with many
resistant NAs [30].
Although the H274Y mutation, which confers resistance to
oseltamivir, is the most commonly detected mutation in influenza
N1 viruses, there are increasing numbers of reports of mutations at
residue I222 (I223 N1 numbering) including I222T/V/M/L
conferring reduced NAI susceptibility in pandemic H1N1,
seasonal H1N1 and H5N1 influenza strains. We identified five
viruses with I222T or I222V mutations with IC50s in the 40–
75 nM range, and three with I222M mutations, two with IC50s
greater than 250 nM. Unlike the H274Y which only confers
resistance in the N1 subtype, I222 mutations cause reduced
susceptibility in N1 [11,27,33–40], N2 [41] and influenza B
[27,42–44] NAs, and have been detected after oseltamivir
treatment in patients and in vitro exposure, but also spontaneously
without drug exposure. Of approximately 1500 highly pathogenic
H5N1 NA sequences in the NCBI Influenza Virus Resource, we
found four I222V, four I222L, seven I222T, one I222Q and one
I222M, an incidence of 1%. All mutations were found in clade 2
strains, with only the I222T found in clade 1 sequences. Although
mutations at I222 generally only reduce susceptibility by less than
20-fold, what is of more concern is that they act synergistically to
increase resistance to very high levels with H274Y [35,37,41] and
E119V mutations. Our results suggest that the I222 mutations
may also act synergistically with the H252Y mutation in the clade
2 viruses. Hurt et al. [35] generated I222V and I222M H5N1
mutants in a clade 1 background, and IC50s in their MUNANA
based assay were 5 and 27 nM respectively. In contrast ours were
10-fold higher than these, with an IC50 greater than 250 nM for
the I222M viruses, indicating that H252Y difference in the clade
2.1 background sequence also contributed to the higher IC50s.
Interestingly the I222M mutation only had a small impact on
peramivir binding, which also requires reorientation of E276 to
form the hydrophobic pocket to accommodate its side chain
[32,45]. However even the H274Y mutation has less impact on
peramivir binding compared to oseltamivir [30]. Similarly the
H252Y difference between clade 1 and 2 viruses had a minimal
effect on peramivir binding. This lack of effect may be due to the
additional strong interactions of the 4-guanidinium group on
peramivir.
We identified a virus with an I117V mutation, which although
statistically was not an outlier, its IC50 for oseltamivir was well
above the median IC50. There are more than 40 H5N1 viruses in
the public sequence data bases with this mutation, and others have
reported the spontaneous emergence of this mutation in H5N1
viruses from infected untreated ferrets [34] as well as in oseltamivir
treated ferrets [46]. While others have reported I117V only
confers a small difference in susceptibility in H5N1 isolates
[11,12,28,47], it has recently been demonstrated that the I117V
acts synergistically with the H274Y mutation to increase
oseltamivir and peramivir resistance to levels that would be of
clinical concern [48]. Our results demonstrated that this mutation
also affected the kinetics of oseltamivir binding compared to the
wild type, hence it also appears to be acting synergistically with the
H252Y mutation to further decrease oseltamivir susceptibility. We
identified three additional isolates with IC50s in the 30 nM range
which also demonstrated loss of slow binding. None of these had
known mutations conferring altered susceptibility or mutations in
conserved residues, but this demonstrates that there may be
numerous changes which can also act synergistically with the
H252Y to further reduce efficacy of oseltamivir binding.
We demonstrated that the decreased susceptibility to oseltamivir
seen in some Cambodian isolates correlated with an S246G
mutation, in agreement with Rameix-Welti et al. [15]. Residue
246 is reported to mediate hydrogen bonded interactions with the
substrate and inhibitors [49]. There was a recent report that the
S246G mutation had no impact on oseltamivir susceptibility in
Cambodian isolates [14]. However they used the chemilumines-
cent assay, and relative drug susceptibility can differ between this
and the MUNANA based assay we used [26]. An S246N mutation
was also reported to cause a 24-fold reduction in oseltamivir
susceptibility in isolates from Laos [11]. Fortunately the S246G
mutation that we saw in our 2005 isolates appeared to be a limited
cluster.
While the resistant viruses here were identified by statistical
analysis, compared to the wild type clade 1.1 reference virus some
of these viruses were between 50- and 500-fold resistant, but only
2- to 20-fold resistant to the clade 2.1 reference virus. However,
there is no consensus on a definition of resistance that is known to
relate to clinical failure. Many laboratories use a 10-fold change in
IC50 in the enzyme inhibition assay compared to the wild type
IC50, however since some viruses have a higher base line IC50, e.g.
influenza B [26] and the clade 2.1 HPAI H5N1 strains, such
Figure 3. Identification of additional clade 2.1 viruses with
altered oseltamivir binding by IC50 kinetics. Comparison of IC50s
after each 10 min without preincubation of virus with inhibitor (2) and
with a 30 min preincubation (+) of virus with inhibitor. After addition of
MUNANA substrate both assays were incubated for 60 min. Lower
initial 10 min IC50s in the (+) reaction compared to the final 60 min IC50s
in the (2) reaction indicates slow binding. Similar IC50s in both assays
demonstrate both fast binding and dissociation. These four isolates all
demonstrated further loss of slow binding compared to the wild type
clade 2.1 reference virus, although only one had a known mutation
conferring reduced oseltamivir susceptibility. Cl 2 wt=Clade 2.1 wild
type A/chicken/Bangli/BBVD-563/2007, Tang=A/chicken/West Java
Tangerang/PTB6/2008, Tanjun = A/chicken/West Java/Tja-31/2008,
Bangli = A/chicken/Bangli/BBVD-562/2007 (I117V mutation),
Paya=A/chicken/Payakumbuh/BPPVRII-307/2007.
doi:10.1371/journal.pone.0066105.g003
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viruses may be clinically resistant with only a few fold increase in
IC50 compared to their wild type counterparts. The IC50 values
also vary between the chemiluminescent and fluorescent enzyme
inhibition assays [19,26]. Furthermore our IC50 kinetics experi-
ments demonstrate how the IC50 can change with incubation
times in the NAI assays. However, for the drugs to have some
therapeutic benefit the levels in vivo would need to be significantly
higher than the IC50s. The levels of oseltamivir in plasma are
estimated to be in the range from 400 to 1200 nmol/L [50,51].
Levels in saliva are estimated to be less than 5% of plasma levels
[52]. Thus levels in the upper respiratory tract may be significantly
lower than 100 nM. With IC50s for oseltamivir for many of these
outliers detected here.50 nM, they could present an even greater
challenge for effective treatment with oseltamivir.
There are nine conserved residues in the NA active site which
contact the sialic acid substrate, and a further ten residues which
provide structural stability to these residues [23,53]. Mutations
conferring altered susceptibility to the NAIs have been mostly
located within these amino acids [25]. However, the more the
effects of mutations on the function of the NA are analyzed, the
more it is obvious that non-active site residues can have subtle, but
important effects on the enzyme function and stability. This was
observed recently when an oseltamivir-resistant A/Brisbane/59/
2007 like H1N1 virus emerged with an H274Y mutation, which
rapidly spread globally, demonstrating no loss of fitness compared
to the wild type virus. It has been demonstrated that three
mutations (R222Q, V234M, D344N) compensated for the impact
on fitness of the H274Y mutation [54,55]. Our demonstration of
differences in the kinetics of oseltamivir binding in NAs with no
previously identified mutations emphasizes the need for pheno-
typic surveillance to detect the subtle effects of drift mutations on
NAI susceptibility.
Since the emergence of the pandemic H1N1/09 virus there
appears to be more complacency about the pandemic potential of
HPAI H5N1 strains. However HPAI H5N1 viruses continue to
spread and evolve and surveillance is of critical importance to
inform on both the antigenic variation for vaccine preparation, as
well as their antiviral susceptibilities. Pending the development of a
suitable vaccine, antivirals will be the first line of defence in any
new pandemic. Our analysis of the NAI susceptibility of 155 virus
isolates from Indonesia identified eight (5%) outliers with reduced
oseltamivir susceptibility with I222 mutations and a further four
viruses also demonstrated loss of slow binding of oseltamivir. In
comparison, even with the use of oseltamivir, only 1% of
pandemic H1N1 isolates from humans have the H274Y mutation
conferring oseltamivir resistance. The higher incidence of these
I222 mutations that we observed is unexpected and of concern.
Widespread phenotypic analysis of susceptibility of avian influenza
HPAI H5N1 viruses to the NAIs needs to be carried out where the
virus is endemic in poultry, to be able to respond in a timely




167 HPAI H5N1 avian influenza isolates from both commercial
farms and the domestic sectors in SE Asia, were isolated from
chickens, ducks, geese, quail and a dog. Indonesian isolates were
supplied to AAHL as part of the FAO-implemented OFFLU
technical project for monitoring the evolution of the HA gene.
Isolates from Thailand were kindly provided by Dr Somjai
Kamolsiripichaiporn, Department of Livestock Development,
Bangkok, Thailand and Cambodian isolates were kindly provided
by Dr Ren Theary, National Animal Health and Production
Investigation Centre (NAHPIC), Department of Animal Produc-
tion and Health, Phnom Penh, Cambodia. Viruses were amplified
in specific pathogen free eggs under BSL3 conditions in the
Diagnosis, Surveillance and Response group at CSIRO AAHL.
Allantoic fluids were then gamma irradiated, prior to use in the
fluorescent based NA inhibition assay.
Chemicals and Inhibitors
Zanamivir and peramivir were kindly provided by GlaxoS-
mithKline (Stevenage, UK). Oseltamivir carboxylate was obtained
by hydrolysis of oseltamivir phosphate (kindly provided by Dr
Keith Watson Walter and Eliza Hall Institute, Australia). Dilutions
of the inhibitors ranged from 0.001 nM to 10,000 nM. The
fluorescent substrate 4-Methylumbelliferyl N-acetyl-a-D-neurami-
nic acid (MUNANA) was obtained from Sigma (Australia) or
Carbosynth (Berkshire, U.K.).
Enzyme Inhibition Assay
The MUNANA based fluorescent assay [56] was used for
measuring drug inhibition. Final concentrations in the assay were
50 mM sodium acetate pH 5.5, 5 mM CaCl2 and 100 mM
MUNANA. We used a BMG FLUOstar Optima reader with
355 nM excitation and 460 nM emission filters for all fluorescent
assays. All samples were screened in duplicate against zanamivir
and oseltamivir in a standard end point assay, with 30 min
preincubation of inhibitor and virus followed by a 60 min reaction
with MUNANA substrate. Stop solution was then added, and total
fluorescent units (FU) were then measured.
Those that showed elevated IC50s were further evaluated in the
IC50 kinetics assay to understand whether the elevated IC50s
resulted from faster binding and/or faster dissociation as recently
described [30,32]. IC50s for end point or kinetics assays were
calculated as the concentration of inhibitor resulting in a 50%
reduction in FU compared to the control. The IC50 kinetics uses
continuous real time monitoring of the enzyme reaction and two
separate assays. The first assay has the standard 30 min
preincubation of virus and inhibitor prior to the addition of
substrate. The second assay has the simultaneous addition of virus,
inhibitors and MUNANA. Fluorescence for both assays is
monitored at 1 min intervals for 60 min after addition of substrate
to ensure a stable signal, and IC50s are calculated after each
10 min interval. IC50s were then plotted as bar graphs for each of
the 10 min time points for both assays.
Statistical Analysis
Box and whisker plots were used to identify outliers with
elevated IC50s [26,27]. Means of the duplicate log10 IC50s for each
sample for each drug were plotted with the box containing 50% of
the samples, representing the 25% to 75% quartiles. The value
between these two represents the interquartile range (IQR).
Outliers were identified as mild if they were between 1.5 and 3.0
times the IQR from the 75th percentile, or as extreme if they were
more than 3.0 IQR from the 75th percentile. The whiskers
represent the 95% confidence limits.
Sequencing
Viral RNA was extracted using the QIAamp Viral RNA Mini
Kit (Qiagen, Germany). The viral NA was amplified with the
SuperScriptTM III One-Step RT-PCR system (Invitrogen, USA)
by gene specific primers (sequences available upon request). The
amplicons were gel-purified (QIAquick, Qiagen) and directly
sequenced using the BigDyeH Terminator (BDT) v3.1 Cycle
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Sequencing Kit (Applied Biosystems) according to manufacturer’s
instructions. Sequencing reactions were purified with the BigDyeH
X-TerminatorTM purification kit (Applied Biosystems) and ana-
lyzed using the Applied Biosystems 3130xl Genetic Analyzer. Full
length neuraminidase gene sequences obtained by this study were
submitted into GenBank with the accession numbers KC791636-
KC791685, KC820950-KC820962, and KC831446-KC831550.
Accession numbers for viruses named in the manuscript are listed
in Table S1. Multiple sequence alignments and translation were
carried out using the Bioedit program to identify potential
variations associated with altered drug susceptibility [57].
Supporting Information
Table S1 Accession Numbers of isolates.
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